Efficacy and Tolerability of a New Non-Extrafine Formulation of Beclomethasone HFA-134a in Patients with Asthma . Jean Paul Rocca-Serra, Eric Vicaut, Gerard Lefrancois, Alberto Umile.

The best delivery of a drug in ventilated neonates is obtained when using a small particle diameter solution administered via a spacer. Lung deposition of hydrofluoroalkane beclomethasone ...

A total of 498 patients entered the run-in phase, of whom 473 received randomised treatment and 443 were included in the ITT analysis [293 (66.1%) to beclomethasone HFA and 150 (33.9%) to ...

Qvar Redihaler (beclomethasone HFA, Teva) has been approved in children aged 4 years and older. This device, however, requires some skill and cannot be used with a holding chamber device.

Seventy-two studies were included in the meta-analysis; treatments evaluated included beclomethasone hydrofluoroalkane (HFA), beclomethasone aqueous, budesonide, ciclesonide HFA, ciclesonide aqueous, ...

Israel-based Teva Pharmaceutical Industries has launched QVAR RediHaler (beclomethasone dipropionate HFA) Inhalation Aerosol in the US for the treatment and control of asthma in patients aged four and ...

QVAR ® RediHaler ™ administers the same active ingredient found in the previously available QVAR ® (beclomethasone dipropionate HFA) Inhalation Aerosol, but utilizes innovative breath-actuated ...

Teva announced today that QVAR RediHaler (beclomethasone dipropionate HFA) Inhalation Aerosol is now commercially available to patients in both 40 mcg and 80 mcg strengths by prescription in the U.S.

Teva announced the launch of Qvar RediHaler (beclomethasone dipropionate HFA) Inhalation Aerosol for the maintenance treatment of asthma as a prophylactic therapy in patients aged 4 years and older.

QVAR RediHaler (beclomethasone dipropionate HFA) Inhalation Aerosol is indicated for the maintenance treatment of asthma as prophylactic therapy in patients 4 years of age or older.